Study of Biobeat Digital Home Monitoring After Elective Lung Cancer Thoracic Surgery to Improve Postoperative Care and Reduce Emergency Visits

What this Trial Is About

Researchers are evaluating the feasibility of using the Biobeat digital home monitoring platform to support patients after thoracic surgery. The study compares this new digital monitoring approach with the current standard care, aiming to see if it reduces unplanned emergency department visits and improves patients quality of life. This trial is designed as a single center, randomized controlled study focusing on elective lung cancer surgery patients. Participants are randomly assigned to one of two groups. The control group receives standard care without home monitoring after hospital discharge. The intervention group is provided with a Biobeat digital monitoring kit, including devices to measure non-invasive blood pressure, pulse oximetry, heart rate, and pain scores. They will use these devices twice daily for two weeks, with continuous ECG monitoring via a two-lead patch to detect irregular heart rhythms. Digital communication with healthcare providers is maintained for four weeks post-surgery. During the study, researchers will track patient data collection, recruitment feasibility, and logistics for a future larger trial. They will monitor emergency department visits and hospital readmission rates within 30 days after discharge. Participants vital signs and pain levels will be reviewed regularly, supported by digital tools. The study lasts for four weeks of active monitoring, with overall feasibility assessed over one year. This approach aims to improve postoperative care through remote monitoring and better communication.

Biobeat Digital Home Monitoring Feasibility